Technology | November 20, 2013

Gallium-68 DOTATOC Receives FDA Orphan Drug Designation for NET Management

Radiopharmaceuticals and tracers nuclear molecular imaging pet systems SNMMI
November 20, 2013 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced that the U.S. Food and Drug Administration (FDA) has designated the radiopharmaceutical Gallium-68 (DOTA0-Phel-Tyr3) octreotide (Ga-68 DOTATOC) as an orphan drug for the management of neuroendocrine tumors (NET). This designation may lead to faster approval of the agent, which would greatly benefit NET patients in the United States. Currently, there are only a few small U.S.-based clinical trials for Ga-68 labeled NET positron emission tomography (PET) agents available for patients, who must otherwise travel out of the country if the scan is required to manage their disease.
In August 2013, SNMMI’s Clinical Trials Network (CTN) submitted an application to the FDA for orphan drug designation for Ga-68 DOTATOC under the Orphan Drug Act. This act provides for granting special status to a drug or biological product to treat a rare disease or condition. For a drug to qualify for orphan designation, the disease or condition must affect fewer than 200,000 people. With a prevalence of approximately 110,000 patients in the United States with NETs, Ga-68 DOTATOC meets this requirement.
With this new orphan drug designation, Ga-68 DOTATOC will be directed down a unique pathway within the FDA. On its road to approval, fewer patients will likely be required for clinical trials, and funds may be available for studies through the Office of Orphan Products Development (OOPD) grant program to support the clinical development of products where the proposed product will be superior to the existing product (Octreoscan). 
“The next step in this process will be to meet with FDA officials to discuss the data needed for regulatory approval, factoring in the extensive literature on the safety and efficacy of this agent and the patients currently enrolled in an ongoing prospective trial,” said Michael Graham, Ph.D., M.D. and co-chair, CTN.
SNMMI’s CTN will remain involved in the clinical trials for Ga-68-labeled DOTA agents as new studies begin. CTN has developed a comprehensive repository of materials to aid in the initiation and conduct of clinical trials including release criteria, an imaging manual, data collection forms and a template investigational new drug (IND) application for Ga-68 agents to help increase investigational use.
 “I think I speak for all NET patients when I say this is a great first step towards approval of this agent in the United States,” said Josh Mailman, chairman, SNMMI’s Patient Advocacy Advisory Board and president, NorCalCarciNET. “Ga-68-labeled NET PET radiopharmaceuticals will reduce the time it takes to image a NET patient from 2-3 days to just a few hours. It has also been shown in early studies in the U.S. and those overseas to change treatment paths for a number of patients. Lastly, the exposed dose of radiation is lower than the current standard of care. ”
For more information:

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...